P. W. O'connor, D. Li, and M. S. Freedman, A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses, Neurology, vol.66, pp.894-900, 2006.

C. Confavreux, D. K. Li, and M. S. Freedman, Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years, Mult Scler, vol.18, pp.1278-1289, 2012.

P. O'connor, J. S. Wolinsky, and C. Confavreux, Randomized trial of oral teriflunomide for relapsing multiple sclerosis, N Engl J Med, vol.365, pp.1293-1303, 2011.

C. Confavreux, P. O'connor, and G. Comi, Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebocontrolled, phase 3 trial, Lancet Neurol, vol.13, pp.247-256, 2014.

L. Kappos, R. Gold, and D. H. Miller, Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study, Lancet, vol.372, pp.1463-1472, 2008.

R. Gold, L. Kappos, and D. L. Arnold, Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis, N Engl J Med, vol.367, pp.1098-1107, 2012.

R. J. Fox, D. H. Miller, and J. T. Phillips, Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis, N Engl J Med, vol.367, pp.1087-1097, 2012.

M. Hutchinson, R. J. Fox, and E. Havrdova, Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsingremitting multiple sclerosis: a systematic review and mixed treatment comparison, Curr Med Res Opin, vol.30, pp.613-627, 2014.

A. Boster, J. Nicholas, and N. Wu, Comparative effectiveness research of diseasemodifying therapies for the management of multiple sclerosis: analysis of a large Health insurance claims database, Neurol Ther, vol.6, pp.91-102, 2017.

D. Ontaneda, J. Nicholas, and M. Carraro, Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US, Mult Scler Relat Disord, vol.27, pp.101-111, 2019.

S. Braune, S. Grimm, and P. Van-hövell, Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry, J Neurol, vol.265, pp.2980-2992, 2018.

E. D'amico, A. Zanghì, and G. Callari, Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in relapsing-remitting multiple sclerosis: an Italian real-word multicenter experience, Ther Adv Neurol Disord, vol.11, p.1756286418796404, 2018.

C. Confavreux, D. A. Compston, O. R. Hommes, W. I. Mcdonald, and A. J. Thompson, EDMUS, a European database for multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.55, pp.671-676, 1992.

C. H. Polman, S. C. Reingold, and B. Banwell, Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, Ann Neurol, vol.69, pp.292-302, 2011.

D. L. Rotstein, B. C. Healy, M. T. Malik, T. Chitnis, and H. L. Weiner, Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort, JAMA Neurol, vol.72, pp.152-158, 2015.

S. R. Cole and M. A. Hernán, Constructing inverse probability weights for marginal structural models, Am J Epidemiol, vol.168, pp.656-664, 2008.

M. S. Ali, R. Groenwold, and S. V. Belitser, Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review, J Clin Epidemiol, vol.68, pp.112-121, 2015.

P. C. Austin, An introduction to propensity score methods for reducing the effects of confounding in observational studies, Multivariate Behav Res, vol.46, pp.399-424, 2011.

M. A. Brookhart, S. Schneeweiss, K. J. Rothman, R. J. Glynn, J. Avorn et al., Variable selection for propensity score models, Am J Epidemiol, vol.163, pp.1149-1156, 2006.

J. A. Myers, J. A. Rassen, and J. J. Gagne, Effects of adjusting for instrumental variables on bias and precision of effect estimates, Am J Epidemiol, vol.174, pp.1213-1222, 2011.

D. Y. Lin and L. J. Wei, The robust inference for the Cox proportional hazards model, J Am Stat Assoc, vol.84, pp.1074-1078, 1989.

J. Xie and C. Liu, Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data, Stat Med, vol.24, pp.3089-3110, 2005.

L. Borgne, F. Giraudeau, B. Querard, A. H. Giral, M. Foucher et al., Comparisons of the performance of different statistical tests for time-to-event analysis with confounding factors: practical illustrations in kidney transplantation, Stat Med, vol.35, pp.1103-1116, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02153379

M. Zwarenstein and S. Treweek, What kind of randomized trials do we need?, CMAJ, vol.180, pp.998-1000, 2009.

E. Gayat, M. Resche-rigon, J. Y. Mary, and R. Porcher, Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study, Pharm Stat, vol.11, pp.222-229, 2012.

L. Barbin, C. Rousseau, and N. Jousset, Comparative efficacy of fingolimod vs natalizumab: a French multicenter observational study, Neurology, vol.86, pp.771-778, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01299977

E. R. Petersen, A. B. Oturai, and N. Koch-henriksen, Smoking affects the interferon beta treatment response in multiple sclerosis, Neurology, vol.90, pp.593-600, 2018.